GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Phase 1/2 Not yet recruiting 126 enrolled Suzhou Genhouse Bio Co., Ltd. Zhejiang Cancer Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation.

Timeline

Start: 2024-07-01
Primary completion: 2027-09-30
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D-1553	Unknown	—	Oral
Subject	GH21	Unknown	—	Oral

Indications

No indication recorded.